Silence Therapeutics plc (SLN) Research

Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.

Open Silence Therapeutics plc (SLN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.